Microbix Biosystems Inc. sees a modest uptick in stock price amidst recent developments.
Microbix Biosystems Inc. (MBX.TO) experienced a 3.33% price increase in today's trading, closing at C$0.31. This week, the stock has remained steady, reflecting a year-to-date gain of 29.17%. While there were no major company announcements this week, recent headlines indicate ongoing developments within the companyโs operations and financial results.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Microbix Biosystems Inc.
MBX.TO
MBX.TO
Microbix Biosystems Inc.
WealthAwesomeMarket cap
$41.25M
52W high
$0.34
52W low
$0.21
1W change
+0.00%
Beta
0.57
Analyst Price Targets
Based on analyst covering MBX
Wall Street analysts forecast MBX stock price to rise 29.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.40
+29.0% Upside
Current Price
C$0.31
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MBX's historical volatility
30-Day Vol
48.0%
Annualized
90-Day Vol
51.8%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$0.37
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$0.33 | C$0.28 โ C$0.39 |
| 60 trading days | C$0.35 | C$0.28 โ C$0.44 |
| 90 trading days | C$0.37 | C$0.28 โ C$0.49 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: The recent increase in Microbix's stock price may signal investor interest amid incremental improvements in the company's financial performance and product offerings.
C$0.31 closing price with a 3.33% gain today.
Microbix's stock has shown resilience with a 29.17% increase year-to-date, despite ongoing operational challenges.
Bull case
Microbix's recent financial results show a 13% revenue increase in Q1 2026, suggesting a positive trend. The company's advancements in molecular pathology and test-ingredient manufacturing could strengthen its market position and revenue potential.
Bear case
Despite these positive developments, Microbix still faces challenges, including a negative profit margin of -38.6%. Its stock price remains below analyst targets, and the company's reliance on a limited product range and ongoing losses could pose risks for investors.
Recent Price Action
Microbix Biosystems Inc. closed today at C$0.31, marking a 3.33% increase. Over the past week, the stock has held steady, with no significant fluctuations in price. Year-to-date, the stock has appreciated by 29.17%, reflecting growing investor interest.
Company Developments
While no major company news has emerged this week, recent headlines indicate that Microbix has reported a 13% revenue growth in Q1 2026, amounting to $4.2 million. Additionally, the company has been actively presenting its molecular pathology platform, which may enhance its offerings in the health care sector.
Technical Picture
Microbix's stock is currently trading above its 50-day moving average of C$0.28 and its 200-day moving average of C$0.25, indicating a positive short- to medium-term trend. The stock has a 52-week range of C$0.21 to C$0.34, suggesting that it is currently trading at 77% of its 52-week high. With a beta of 0.57, the stock is less volatile than the broader market.
Insider Activity
There are no recent insider trading activities reported for Microbix Biosystems Inc. This lack of insider transactions may indicate stability within the company's management and operational strategy.
Price Action Summary
As of the latest close, Microbix Biosystems Inc. (MBX.TO) stands at C$0.31, reflecting a 3.33% gain today. Investors will be monitoring future developments as the company continues to navigate its growth trajectory in the health care sector.
Advertisement
